Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples